Skip to main content
S

SCL Science Inc. — Investor Relations & Filings

Ticker · 246960 ISIN · KR7246960009 KO Professional, scientific and technical activities
Open in API
Filings indexed 310 across all filing types
Latest filing 2022-02-16 Proxy Solicitation & In…
Country KR South Korea
Listing KO 246960

About SCL Science Inc.

https://sclscience.com/en

SCL Science Inc., formerly InnoTherapy Inc., is a healthcare company focused on digital innovation and advanced medical technologies. The company develops and commercializes medical hemostatic agents based on its proprietary biomimetic technology, including the Bio-inspired Medical Materials (BiMM) product line. Leveraging 40 years of expertise in medical science, SCL Science is also dedicated to building a digital healthcare ecosystem using artificial intelligence and high-quality medical data. Its services extend to clinical trial analysis, bio-logistics, and an expanding drug discovery platform focused on AI-driven cancer vaccine development. The company serves hospitals, research laboratories, and other medical institutions.

Recent filings

Filing Released Lang Actions
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for InnoTherapy. It outlines the date, location, and specific agenda items (such as approval of financial statements, election of directors, and remuneration limits). This type of document is a standard proxy solicitation material sent to shareholders to inform them of the meeting and request their votes, which falls under the Proxy Solicitation & Information Statement category.
2022-02-16 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 1% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the acquisition of shares by Asset One Asset Management in the company Inotherapy. This type of filing is specifically used to notify the market when an entity crosses a significant ownership threshold (typically 5%). It does not fit into categories like 'Director's Dealing' (which is for individual insiders) or 'M&A Activity' (which is for corporate takeovers). Since it is a specific regulatory disclosure of share ownership, it falls under the 'Major Shareholding Notification' category.
2022-01-11 Korean
전환가액의조정(제2회차)
Share Issue/Capital Change Classification · 1% confidence The document is a formal regulatory filing from InnoTherapy regarding the adjustment of the conversion price for its 2nd series convertible bonds due to a decline in market price. This type of disclosure relates to changes in the company's capital structure and financial instruments. Among the provided categories, 'CAP' (Capital/Financing Update) is the most appropriate as it covers updates on financing activities and capital structure changes, including adjustments to convertible debt terms.
2022-01-10 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 1% confidence The document is a short regulatory notice regarding the setting of a record date and shareholder register closure for an upcoming Annual General Meeting (AGM). It does not contain the full AGM materials or voting results, but rather serves as a formal regulatory announcement of the procedural steps for the meeting. Given it is a standard regulatory notification that does not fit into specific categories like 'AGM-R' (which implies presentation materials) or 'DVA' (which implies results), it falls under the general regulatory filing category.
2021-12-15 Korean
분기보고서 (2021.09)
Interim / Quarterly Report Classification · 1% confidence The document is a '분기보고서' (Quarterly Report) for the company 'InnoTherapy, Inc.' covering the period from January 1, 2021, to September 30, 2021. It contains detailed financial statements, management discussion and analysis, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2021
2021-11-12 Korean
전환가액의조정(제2회차)
Share Issue/Capital Change Classification · 1% confidence The document is an official regulatory filing from the Korea Exchange (KRX) regarding the adjustment of the conversion price for convertible bonds (CB). It details the change in conversion price and the resulting change in the number of convertible shares due to a decline in market price. This type of corporate action, specifically related to capital structure and debt-to-equity conversion terms, falls under the 'Capital/Financing Update' category.
2021-10-12 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.